ARCHIVES

With $1.1 Billion At Stake, Cancer Groups Mull Comparative Effectiveness Studies

This article is from The Cancer Letter archive.

Vol. 35 No. 20 | May 22, 2009

Download PDF Visit The Full Archive

Related Articles

In Brief: Gregory Curt May Return As Director Of COP; Koop Locked In as Surgeon General Until Nov.

January 20, 1989

Phase III Trial Would Give Clearer Picture Of C225 Role.

February 15, 2002

Committee, BSC Recommend Against Continuing Women’s Health Trial; Appeal to NCAB Seen

January 15, 1988

High Risk Youth Targeted In Concept Ok’d By Advisors

February 8, 1991

Vasopermeation Technology Awarded Patent For CA Firm.

September 28, 2001

Three cancer societies to be led by Vanderbilt faculty in 2004

July 18, 2003